Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer
TUESDAY, May 13, 2025 -- For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial, resulting in a reduced risk for all-cause mortality and breast cancer-specific mortality, according to a study published online May 7 in The Lancet Oncology.
Hend Hassan, from the University of Cambridge in the United Kingdom, and colleagues examined the association between BSO and long-term health outcomes in women aged 20 to 75 years carrying pathogenic variants in BRCA1 and BRCA2 and with a personal history of breast cancer. The analyses used data from the National Cancer Registration Dataset and the Hospital Episode Statistics-Admitted Patient Care dataset, and included 1,674 BRCA1, 1,740 BRCA2, and nine BRCA1 and BRCA2 carriers who were diagnosed with breast cancer between 1995 and 2019.
The researchers found that uptake of BSO was significantly lower among Black and Asian versus White women (odds ratios, 0.48 and 0.47, respectively). Women living in the least socioeconomically deprived areas had higher BSO uptake (odds ratio, 1.38 versus most deprived). For both BRCA1 and BRCA2 pathogenic variant carriers, BSO was associated with a reduced risk for all-cause mortality (hazard ratio, 0.52) and with reduced breast cancer-specific mortality (hazard ratios, 0.62 and 0.48 for BRCA1 and BRCA2, respectively). In the combined BRCA1 and BRCA2 sample, BSO was also associated with a reduced risk for a second non-breast cancer (hazard ratio, 0.59). In the combined sample, BSO was not associated with an increased risk for cardiovascular diseases, ischemic heart disease, cerebrovascular disease, non-breast cancer-specific mortality, contralateral breast cancer, or depression.
“Our findings will be crucial for counseling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation,” senior study author Antonis Antoniou, Ph.D., also from the University of Cambridge, said in a press release.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.